Atropine eyedrops for treatment of increasing shortsight
- Conditions
- Health Condition 1: H521- Myopia
- Registration Number
- CTRI/2019/10/021538
- Lead Sponsor
- Dr Abraham Kurian
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Children or Young adults in the age group 5-15 years.
2.Myopic refractive error of spherical equivalent > 1.00D as measured by cycloplegic refraction
3.Astigmatism of <1.50D as measured by cycloplegic refraction
4.Documented progression of myopia
5.Ability to understand and follow the study instructions you receive and likely to be amenable for 1 year followup.
6.Normal ocular health other than refractive error
7.Normal Intraocular pressure ( <21 mm Hg)
1.Known Allergy or hypersensitivity to Atropine, Cyclopentolate, Phenyl ephrine or Proparacaine
2.Amblyopia in atleast one eye
3.History of significant cardiac or respiratory illness
4.Current enrolment in another investigational study or participation in such a study within 30 days of entry into this study
5.No previous or current use of contact lenses or bifocals or progressive lenses or other forms of treatment (including Atropine in any strength) for myopia
6.Patient has a condition or situation which in the investigators opinion, may put the patient at a significant risk, may confound the study results, or interfere with the participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression of myopia in terms of Spherical equivalent in realtion to baselineTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method Change in axial length with respect to the baseline measurement.Timepoint: 1 year